May 2026 Br J Cardiol 2026;33:77–8 doi:10.5837/bjc.2026.024
Andrew Chisom Madu, Brian Li, Daniela Toumazi, Muhammad Asad, Aryan Sabir, Duncan Coles, Anthony Dimarco, Henry Oluwasefunmi Savage
Introduction Heart failure (HF) remains a leading cause of hospital admissions and healthcare expenditure worldwide, and is associated with substantial morbidity and mortality.1 HF is commonly classified into three subtypes based on left ventricular ejection fraction (LVEF)1 as heart failure with preserved ejection fraction (HFpEF), LVEF ≥50%; mildly reduced ejection fraction (HFmrEF), LVEF 41–49%; or with a reduced ejection fraction (HFrEF), LVEF ≤40%. Patients with HF are at risk of decompensation due to the inability of the heart to sustain a functional cardiac output. Compensatory mechanisms, such as neurohormonal activation and sa
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits